Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Malignant Melanoma

  Free Subscription


Articles published in Curr Opin Oncol

Retrieve available abstracts of 16 articles:
HTML format



Single Articles


    January 2021
  1. TROJANIELLO C, Vitale MG, Ascierto PA
    Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?
    Curr Opin Oncol. 2021;Publish Ahead of Print.
    PubMed     Abstract available


    December 2020
  2. DUMAZ N, Lebbe C
    New perspectives on targeting RAF, MEK and ERK in melanoma.
    Curr Opin Oncol. 2020;Publish Ahead of Print.
    PubMed     Abstract available


  3. TETU P, Vercellino L, Reger de Moura C, Baroudjian B, et al
    Mitogen-activated protein kinase blockade in melanoma: intermittent versus continuous therapy, from preclinical to clinical data.
    Curr Opin Oncol. 2020 Dec 9. doi: 10.1097/CCO.0000000000000706.
    PubMed     Abstract available


    March 2020
  4. GIUFFRIDA R, Conforti C, Di Meo N, Deinlein T, et al
    Use of noninvasive imaging in the management of skin cancer.
    Curr Opin Oncol. 2020;32:98-105.
    PubMed     Abstract available


    December 2019
  5. TETU P, Baroudjian B, Lebbe C
    Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting.
    Curr Opin Oncol. 2019 Dec 27. doi: 10.1097/CCO.0000000000000614.
    PubMed     Abstract available


  6. HERRSCHER H, Robert C
    Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting.
    Curr Opin Oncol. 2019 Dec 23. doi: 10.1097/CCO.0000000000000610.
    PubMed     Abstract available


  7. DELYON J, Lebbe C, Dumaz N
    Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.
    Curr Opin Oncol. 2019 Dec 12. doi: 10.1097/CCO.0000000000000606.
    PubMed     Abstract available


  8. MOURAH S, Louveau B, Dumaz N
    Mechanisms of resistance and predictive biomarkers of response to targeted therapies and immunotherapies in metastatic melanoma.
    Curr Opin Oncol. 2019 Dec 10. doi: 10.1097/CCO.0000000000000603.
    PubMed     Abstract available


    January 2019
  9. SUPPA M, Gandini S
    Sunbeds and melanoma risk: time to close the debate.
    Curr Opin Oncol. 2019 Jan 22. doi: 10.1097/CCO.0000000000000507.
    PubMed     Abstract available


    January 2018
  10. KOELBLINGER P, Thuerigen O, Dummer R
    Development of encorafenib for BRAF-mutated advanced melanoma.
    Curr Opin Oncol. 2018 Jan 18. doi: 10.1097/CCO.0000000000000426.
    PubMed     Abstract available


    December 2017
  11. DIMITRIOU F, Braun RP, Mangana J
    Update on adjuvant melanoma therapy.
    Curr Opin Oncol. 2017 Dec 18. doi: 10.1097/CCO.0000000000000432.
    PubMed     Abstract available


  12. CHENG PF
    Medical bioinformatics in melanoma.
    Curr Opin Oncol. 2017 Dec 8. doi: 10.1097/CCO.0000000000000428.
    PubMed     Abstract available


  13. CHUA V, Aplin AE
    Novel therapeutic strategies and targets in advanced uveal melanoma.
    Curr Opin Oncol. 2017 Dec 4. doi: 10.1097/CCO.0000000000000425.
    PubMed     Abstract available


    September 2017
  14. SILVA IP, Long GV
    Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice.
    Curr Opin Oncol. 2017 Sep 12. doi: 10.1097/CCO.0000000000000405.
    PubMed     Abstract available


  15. WARNER SG, O'Leary MP, Fong Y
    Therapeutic oncolytic viruses: clinical advances and future directions.
    Curr Opin Oncol. 2017;29:359-365.
    PubMed     Abstract available


    December 2016
  16. DUMMER R, Ramelyte E, Levesque M, Goldinger SM, et al
    Critical aspects to achieve a high-quality melanoma clinic.
    Curr Opin Oncol. 2016 Dec 23. doi: 10.1097/CCO.0000000000000357.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: